StockNews.com began coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a research note released on Monday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Price Performance
Shares of NASDAQ TTNP opened at $3.54 on Monday. The business’s 50-day simple moving average is $3.60 and its 200-day simple moving average is $4.09. Titan Pharmaceuticals has a 52 week low of $3.03 and a 52 week high of $14.80.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last released its quarterly earnings results on Friday, January 3rd. The specialty pharmaceutical company reported ($0.83) EPS for the quarter.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Further Reading
- Five stocks we like better than Titan Pharmaceuticals
- What Investors Need to Know About Upcoming IPOs
- What GTC 2025 Signals for NVIDIA Stock’s Next Big Move
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Alphabet’s Officially In A Bear Market—Time To Buy?
- EV Stocks and How to Profit from Them
- D-Wave and Quantum Supremacy: Implications For Investors
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
